Robert Boyle

Robert Boyle is an experienced leader in the pharmaceutical and biotechnology sectors, currently serving as the CEO of Sentinel Oncology since April 2005. In addition to this role, Boyle is a Board Member at Oxford Drug Design and a Venture Partner at o2h Ventures Limited, both positions held since 2019. Prior experience includes serving as Director at NeoPhore Ltd from October 2017 to January 2019, Senior Research Associate at Astex Pharmaceuticals from October 2003 to April 2005, and Sr Scientist II at Millennium Pharmaceuticals from 2000 to 2003. Earlier in the career, Boyle was a Group Leader at Cambridge Discovery Chemistry from June 1997 to September 2000 and worked as an Associate Scientist at Pfizer from August 1993 to June 1997.